[Allogeneic haematopoietic stem cell transplantation in myelofibrosis: Patient selection, pre-transplant preparation and harmonisation of practices (SFGM-TC)].
Key claim: The SFGM-TC workshop recommends an individualized approach to allogeneic HSCT in myelofibrosis integrating clinical and molecular prognostic scores, transplant-related risk assessment, and peri-transplant ruxolitinib management, while highlighting unresolved questions around dynamic molecular monitoring.
Abstract
As part of its initiative to harmonize practices in allogeneic hematopoietic stem cell transplantation, the SFGM-TC devoted a workshop to the management of myelofibrosis. Discussions focused on patient selection, peri-transplant management of ruxolitinib, and the choice of conditioning regimen and donor. The workshop emphasized the need for an individualized approach integrating clinical and molecular prognostic scores, assessment of transplant-related risk, and treatment response. Several questions remain open, particularly regarding the role of dynamic molecular monitoring and optimal peri-transplant ruxolitinib management.
Why this matters
Pending synthesis.